Table 1B.
Basic demographic data at baseline [count (percent), mean (standard deviation)] with respect to treatment category.
| Treatment category sodium bicarbonate (mg/kg per day) | |||||
|---|---|---|---|---|---|
| None | 1–37.9 | 38–79 | ≥80 | p-value | |
| N | 13 | 15 | 10 | 9 | |
| Study group | |||||
| Intervention | 0 | 5 | 10 | 9 | |
| Rescue | 13 | 10 | 0 | 0 | |
| Sex (female) | 5 (39%) | 6 (40%) | 1 (10%) | 6 (67%) | 0.092 |
| Age (years) | 56 (±17.3) | 58 (±15) | 61 (±8.8) | 53 (±16) | 0.741 |
| BMI (kg/m2) | 26 (±4.5) | 31 (±5.4) | 27 (±7) | 27 (±2.8) | 0.083 |
| eGFR (mL/min per 1.73 m2) | 30.3 (±10.3) | 24 (±7.2) | 25 (±9.1) | 25 (±6.7) | 0.338 |
| Serum (mmol/L) | 20.2 (±0.9) | 18.6 (±1.4) | 19 (±1.1) | 17.9 (±2.3) | 0.007 |
| Urine sodium (mmol/24 h) | 207 (±95) | 167 (±79) | 201 (±82) | 181 (±75) | 0.766 |
| Urine pH | 5.7 (1.34) | 5.2 (±0.5) | 5.2 (±0.3) | 5.6 (±0.7) | 0.281 |
| Number of antihypertensives | 35 (2.7 per subject) | 41 (2.7 per subject) | 21 (2.1 per subject) | 15 (1.7 per subject) | 0.001 |
| Type of antihypertensive | |||||
| Diuretics | 8 (62%) | 9 (60%) | 4 (40%) | 2 (22%) | |
| Calcium antagonist | 6 (46%) | 8 (53%) | 4 (40%) | 3 (33%) | |
| ACEi/ARB | 11 (85%) | 12 (80%) | 7 (70%) | 7 (78%) | |
| Beta blocker | 5 (39%) | 8 (53%) | 3 (30%) | 2 (22%) | |
| Others | 5 (39%) | 4 (27%) | 3 (30%) | 1 (11%) | 0.994 |
| Underlying renal disease | |||||
| Glomerulopathy | 4 (31%) | 3 (20%) | 1 (10%) | 4 (44%) | |
| Vascular nephropathy | 5 (39%) | 2 (13%) | 3 (30%) | 1 (11%) | |
| Diabetic nephropathy | 3 (23%) | 5 (33%) | 4 (40%) | 0 | |
| Others | 1 (8%) | 5 (33%) | 2 (20%) | 4 (44%) | 0.200 |
| Comorbidities | |||||
| Arterial hypertension | 12 (92%) | 15 (100%) | 10 (100%) | 8 (89%) | 0.436 |
| Diabetes | 4 (31%) | 4 (27%) | 8 (80%) | 0 | 0.002 |
| Cardiovascular disease | 2 (15%) | 2 (13%) | 3 (30%) | 0 | 0.389 |
| Congestive heart failure | 2 (15%) | 1 (7%) | 1 (10%) | 0 | 0.756 |
| Peripheral occlusive disease | 2 (15%) | 2 (13%) | 2 (20%) | 1 (11%) | 1.000 |
| COPD/Asthma | 2 (15%) | 2 (13%) | 0 | 0 | 0.529 |
Statistical testing was done by means of the Kruskal-Wallis rank sum test for continuous data and by the Fisher Exact test for categorical data.
BMI, body mass index; eGFR, estimated glomerular filtration rate; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease.